{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Transplant+Failure+and+Rejection&page=2",
    "query": {
      "condition": "Kidney Transplant Failure and Rejection",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Kidney+Transplant+Failure+and+Rejection&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T04:01:33.803Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00817206",
      "title": "Safety and Efficacy of LCP-Tacro™ Once Daily in Stable Renal Transplant Patients Converted From Prograf® Twice Daily",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "LCP-Tacro",
          "type": "DRUG"
        },
        {
          "name": "Prograf",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veloxis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2008-12",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2015-09-10",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00817206"
    },
    {
      "nct_id": "NCT05525507",
      "title": "Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Kidney Disease",
        "Immunological Tolerance",
        "Kidney Transplant Failure and Rejection",
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Conditioning and Stem cell infusion",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-12-21",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-11-26",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05525507"
    },
    {
      "nct_id": "NCT03380962",
      "title": "Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Kidney Failure, Chronic",
        "End-Stage Renal Disease",
        "Transplant Glomerulopathy",
        "Transplant;Failure,Kidney",
        "Kidney Transplant Failure and Rejection",
        "Antibody-mediated Rejection",
        "Kidney Transplant; Complications"
      ],
      "interventions": [
        {
          "name": "Clazakizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanley Jordan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "15 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2018-02-27",
      "completion_date": "2025-08-30",
      "has_results": false,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03380962"
    },
    {
      "nct_id": "NCT05983770",
      "title": "Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant Rejection"
      ],
      "interventions": [
        {
          "name": "AT-1501",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eledon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 127,
      "start_date": "2023-08-30",
      "completion_date": "2025-09-25",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 27,
      "location_summary": "Los Angeles, California • Orange, California • Sacramento, California + 23 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05983770"
    },
    {
      "nct_id": "NCT06013865",
      "title": "Empagliflozin Treatment in Kidney Transplant Recipients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Kidney Transplant",
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "VA Office of Research and Development",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 264,
      "start_date": "2024-04-05",
      "completion_date": "2030-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 5,
      "location_summary": "Hines, Illinois • Iowa City, Iowa • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Hines",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06013865"
    },
    {
      "nct_id": "NCT03386539",
      "title": "Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pediatric Heart Transplantation",
        "Immunosuppression",
        "Chronic Kidney Diseases",
        "Cardiac Allograft Vasculopathy",
        "Heart Transplant Failure and Rejection",
        "Post-transplant Lymphoproliferative Disorder",
        "Heart Transplant Infection"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 211,
      "start_date": "2018-01-29",
      "completion_date": "2024-01",
      "has_results": false,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 25,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03386539"
    },
    {
      "nct_id": "NCT01656135",
      "title": "Reference Group Trial for The ONE Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "End-stage Renal Failure",
        "Kidney Graft Rejection"
      ],
      "interventions": [
        {
          "name": "Blood drawing for immune monitoring and questionnaires",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Regensburg",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2012-12",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-03-09",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01656135"
    },
    {
      "nct_id": "NCT01974999",
      "title": "A Retrospective Multicenter Study to Determine 5-Year Clinical Outcomes in Subjects Previously Enrolled in the CTOT-01 Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Kidney Disease",
        "Kidney Failure",
        "End Stage Renal Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 184,
      "start_date": "2013-10",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2019-01-03",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 5,
      "location_summary": "New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01974999"
    },
    {
      "nct_id": "NCT01154387",
      "title": "Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "End Stage Renal Disease",
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "DRUG"
        },
        {
          "name": "TOL101",
          "type": "DRUG"
        },
        {
          "name": "Steroids",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil (MMF)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tolera Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 85,
      "start_date": "2010-07",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-11",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Lexington, Kentucky • Ann Arbor, Michigan + 9 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Livingston",
          "state": "New Jersey"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01154387"
    },
    {
      "nct_id": "NCT02426684",
      "title": "Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Renal Disease"
      ],
      "interventions": [
        {
          "name": "IdeS® (Imlifidase)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 17,
      "start_date": "2015-06-16",
      "completion_date": "2017-11-10",
      "has_results": true,
      "last_update_posted_date": "2022-05-16",
      "last_synced_at": "2026-06-10T04:01:33.803Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02426684"
    }
  ]
}